Benjamin P. Chen, Ph.D
Finance and Corporate Development
Dr. Chen is currently the Managing Partner of Ignatius Capital Management/Ignatius Transaction Partners, LLC – a boutique global lifesciences merchant bank. Previously, he was a Managing Director and an International Director at Burrill & Company, a San Francisco based global life sciences investment firm. In his professional career, Dr. Chen has made numerous contributions in assessing technology, transferring discoveries into the clinic, raising venture investment and establishing strategic partnerships among pharmaceutical and biotech companies. Dr. Chen's merchant banking activities are spread out worldwide and include relationships in Australia, Canada, China, and the United Kingdom. Previously Dr. Chen built talented scientific teams in immunology, genomics, virology, gene therapy and cell biology at Roche Diagnostics, Sentinel Biosciences, Progenesys, and SyStemix (a Novartis company). He played a key role in the IPO of the first biotech start-up that he joined, as well as the acquisition of SyStemix and Sentinel Biosciences by Novartis and Roche Diagnostics. Dr. Chen studied at the University of Wisconsin-Madison and Stanford University.
Bruce Keyt, Ph.D.
Development of MAb Biotherapeutics
Dr. Keyt is a biotechnology industry veteran having almost 30 years of scientific and management experience. Currently he is the Chief Scientific Officer at IGM Biosciences, Inc., a therapeutic company based in Mountain View, CA. Before joining IGM, Dr. Keyt was the CSO and Vice President of Research of Trellis BioScience. He has extensive experience in pre-clinical development, protein chemistry and pharmacology of antibodies and other proteins as therapeutic agents. Prior to Trellis, Dr. Keyt held numerous managerial positions at various antibody therapeutics company including Abmaxis, Inc., Abgenix, Inc, Millenium Pharmaceuticals and Genetech. As Vice President, Preclinical Development at Abgenix, Dr. Keyt led the efforts on the development of more than 20 therapeutics candidates in the field of cancer and inflammation, resulting in the filing of two INDs. Prior to that, he held senior management positions for four years at Millennium Pharmaceuticals, where, as director of biotherapeutics oncology, he led the group for validating targets and developing model systems for preclinical candidates. He began his professional career with a 16-year tenure at Genentech, where his research and development work on 7 major projects led to 6 marketed products such as Factor VIII, Activase tPA, TNKase, as well as therapeutic antibodies, Avastin, Lucentis, and Vectabix. He is an author or co-author of over 50 scientific articles and holding 12 patents. Dr. Keyt holds a Ph.D. degree in biochemistry and pharmacology from Tufts University School of Medicine.
Elizabeth Song, Ph.D.
Licensing and Clinical Market Development
Dr. Song has 25 years of progressive experience in business and corporate development in both established and emerging biotechnology companies. She is currently the Executive Vice President, Strategic Development at CHA Biotech, Co. Ltd, an organization based in both Korea and USA, and Consulting Vice President, Business Development of EGeen International Corporation, a clinical CRO company. She also serves as Advisor to several biotechnology companies, and to Astia, an innovative not-for-profit organization to foster women entrepreneurship. She has been responsible for licensing and business development activities at companies at all developmental stages including start-up (Dios, Virologix), mid-stage (EGeen) and public companies (Lynx Therapeutics). Prior to joining EGeen, Dr. Song was the Director of Business Development and Alliances Management at Lynx Therapeutics, responsible for initiating, negotiating and managing technology development alliances. Before her professional experiences with Lynx and other biopharmaceutical companies, she was Director of Viral Research at Virologix Corporation and senior scientist at Chiron Corporation. Dr. Song completed her postdoctoral fellowship at The Scripps Institute and received her Ph.D. in Genetics from UC Berkeley.
Stephen F. Carroll, Ph.D.
Preclinical R & D
Dr. Carroll is an innovative scientific leader with more than 20 years of industry experience and a broad background in protein biochemistry, pharmacology and toxicology. His industry skills and experience cover the practical and efficient non-clinical evaluation and development of protein therapeutics, including antibodies, antibody fragments, enzymes, conjugates and recombinant proteins. Dr. Carroll was previously employed for 16 years as Vice President, Preclinical Research and Scientific and Product Development at Xoma Ltd, a biotechnology company specializing in the development of antibodies and recombinant proteins for use in inflammation, cancer, autoimmune disorders and infectious disease. Previous to Xoma Dr. Carroll was an Assistant Professor of Microbiology and Molecular Genetics at Harvard Medical School in Boston, Massachusetts, and a Postdoctoral Fellow and Adjunct Lecturer, Microbiology at the University of California, Los Angeles, California. He is the inventor or author of more than 50 US and foreign patents and patent applications and has authored more than 60 publications in peer-reviewed journals.